Education
About Us
Working with TipRanks
Follow Us
Abbvie (GB:0QCV)
:0QCV
0QCV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$159.76 - $244.49
Previous CloseN/A
Volume123.97K
Average Volume (3M)4.41K
Market Cap
$406.64B
Enterprise Value$392.79B
Total Cash (Recent Filing)$6.47B
Total Debt (Recent Filing)$70.48B
Price to Earnings (P/E)108.9
Beta0.65
Next Earnings
Oct 31, 2025EPS Estimate
3.27Last Dividend Ex-Date
Jul 15, 2025Dividend Yield3.88%
Share Statistics
EPS (TTM)2.97
Shares Outstanding1,766,558,200
10 Day Avg. Volume5,738
30 Day Avg. Volume4,406
Financial Highlights & Ratios
PEG Ratio-6.08
Price to Book (P/B)94.54
Price to Sales (P/S)5.58
P/FCF Ratio17.63
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.73
Enterprise Value/Gross Profit9.07
Enterprise Value/Ebitda27.74
Forecast
1Y Price Target
$238.61Price Target Upside2.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of Bretisilocin is a solid addition to AbbVie's Neuro pipeline and fits well with its fast-growing Neuro franchise, which is in the large Major Depressive Disorder category.
Product DevelopmentAbbVie has successfully navigated the largest drug patent expiry in the world, with Humira being replaced by superior products Skyrizi and Rinvoq.
Revenue GrowthRinvoq indication expansion has the potential to add ~$2B to peak sales, further emphasizing the asset's potential value.
Bears Say
Market CompetitionWith increasing macroeconomic pressures, revenues from high-performing assets like Rinvoq have become increasingly important.
Patent ExpiryAbbVie reached a settlement delaying generic competition for Rinvoq to 2037, extending its patent protection.
AbbVie News
0QCV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest share price was $159.76 and its highest was $244.49 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $406.64B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Oct 31, 2025 which is in 22 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Jul 31, 2025. The company reported $2.97 earnings per share for the quarter, beating the consensus estimate of $2.88 by $0.09.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 3.88%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.27.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,558,200 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $2.97 in its last earnings report, beating expectations of $2.88. Following the earnings report the stock price went up 0.25%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in GB:0QCV
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$238.61 (2.59% Upside)
$238.61 (2.59% Upside)
Blogger Sentiment
Bullish
GB:0QCV Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.55%
12-Months-Change
Fundamentals
Return on Equity
112.90%
Trailing 12-Months
Asset Growth
-3.35%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
0QCV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with significant achievements in revenue growth, pipeline advancement, and strategic acquisitions. However, challenges remain in specific segments such as HUMIRA sales and the aesthetics market.View all GB:0QCV earnings summaries0QCV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
0QCV Stock 12 Month Forecast
Average Price Target
$238.61
▲(2.59% Upside)
Technical Analysis
Options Prices
Currently, No data available
---